×

Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

InsideArbitrage Event Driven Monitor – February 13, 2024

  • February 13, 2024

Merger Arbitrage

  1. CBAY: The acquisition of CymaBay Therapeutics, Inc. (CBAY) by Gilead Sciences, Inc. (GILD) for $3.26 billion or $32.50 per share in cash.
  2. SQNS: Shareholders of Sequans Communications (SQNS) approved the company’s merger with Renesas Electronics Corporation at a special meeting of shareholders.
  3. RYZB: Bristol Myers Squibb (BMY) and RayzeBio (RYZB) announced that the waiting period under the HSR Act expired on February 9, 2024. Unless the tender offer is extended, the offer will expire on February 22, 2024.

You can check out new deals, all deal updates, and spreads on active deals in our Merger Arbitrage Tool for premium members here.

Only plus or premium subscribers can access this post. Subscribe today.